Table of Contents Author Guidelines Submit a Manuscript
International Journal of Hypertension
Volume 2013, Article ID 653789, 15 pages
http://dx.doi.org/10.1155/2013/653789
Review Article

Impact of Diabetes on Cardiovascular Disease: An Update

1Department of Internal Medicine, Diabetes Unit, State University of Rio de Janeiro, Avenida 28 de Setembro 77, Terceiro Andar, Vila Isabel, 20551-030 Rio de Janeiro, RJ, Brazil
2Department of Internal Medicine, Bauru's Diabetics Association, Rua Saint Martin 27-07, 17.012-433 Bauru, SP, Brazil

Received 6 December 2012; Revised 31 January 2013; Accepted 31 January 2013

Academic Editor: Mario Fritsch Neves

Copyright © 2013 Alessandra Saldanha de Mattos Matheus et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Wild, G. Roglic, A. Green et al., “Global prevalence of diabetes: estimates for the year 2000 and projections for 2030,” Diabetes Care, vol. 27, no. 5, pp. 1047–1053.
  2. American Diabetes Association, “Standards of medical care for patients with diabetes mellitus,” Diabetes Care, vol. 26, supplement 1, pp. 533–550, 2003. View at Google Scholar
  3. IDF. International Diabetes Federation, Diabetes Atlas, International Diabetes Federation Diabetes Atlas, Brussels, Belgium, 3rd edition, 2006.
  4. C. A. Negrato, J. P. Dias, M. F. Teixeira et al., “Temporal trends in incidence of Type 1 diabetes between 1986 and 2006 in Brazil,” Journal of Endocrinology Investigation, vol. 33, pp. 373–377, 2010. View at Google Scholar
  5. M. I. Harris, “Summary of national diabetes data group,” in Diabetes in America, NIH Publication No. 95-1468, pp. 1–13, Government Printing Office, Washington, DC, USA, 2nd edition, 1995. View at Google Scholar
  6. American Diabetes Association, “Economic costs of diabetes in the US in 2007,” Diabetes Care, vol. 31, pp. 596–615, 2008. View at Google Scholar
  7. L. R. Bahia, D. V. Araújo, B. D. Schaan et al., “The costs of type 2 diabetes mellitus outpatient care in the Brazilian public health system,” Value in Health, vol. 14, pp. S137–S140, 2011. View at Google Scholar
  8. G. Orasanu and J. Plutzky, “The pathologic continuum of diabetic vascular disease,” Journal of the American College of Cardiology, vol. 53, no. 5, pp. S35–S42, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. T. M. Kemp, E. L. M. Barr, P. Z. Zimmet et al., “Glucose, lipid, and blood pressure control in Australian adults with type 2 diabetes: the 1999–2000 AusDiab,” Diabetes Care, vol. 28, no. 6, pp. 1490–1492, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. S. P. Laing, A. J. Swerdlow, S. D. Slater et al., “Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes,” Diabetologia, vol. 46, no. 6, pp. 760–765, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. Centers for Disease Control and Prevention, National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, Atlanta, Ga, USA, 2011.
  12. S. M. Haffner, S. Lehto, T. Ronnemaa et al., “Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction,” The New England Journal of Medicine, vol. 339, no. 4, pp. 229–234, 1998. View at Publisher · View at Google Scholar · View at Scopus
  13. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), “Third report of the National Cholesterol Education Program (NCEP) expert panel on detection,” Circulation, vol. 106, pp. 3143–3421, 2002. View at Google Scholar
  14. U. Bulugahapitiya, S. Siyambalapitiya, J. Sithole, and I. Idris, “Is diabetes a coronary risk equivalent? Systematic review and meta-analysis,” Diabetic Medicine, vol. 26, no. 2, pp. 142–148, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Al Ghatrif, Y. F. Kuo, S. Al Snih, M. A. Raji, L. A. Ray, and K. S. Markides, “Trends in Hypertension Prevalence, Awareness, Treatment and Control in Older Mexican Americans, 1993-2005,” Annals of Epidemiology, vol. 21, no. 1, pp. 15–25, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. American Diabetes Association, “Standards of medical care in diabetes 2011,” Diabetes Care, vol. 34, supplement 1, pp. 11–61, 2011. View at Google Scholar
  17. I. M. Stratton, A. I. Adler, H. A. W. Neil et al., “Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study,” British Medical Journal, vol. 321, no. 7258, pp. 405–412, 2000. View at Google Scholar · View at Scopus
  18. DCCT, “The diabetes control and complications trial,” The New England Journal of Medicine, vol. 329, pp. 977–986, 1993. View at Google Scholar
  19. M. B. Gomes, D. Gianella, M. Faria et al., “Prevalence of patients with diabetes type 2 within the targets of care guidelines in daily clinical practice: a multicenter study of type 2 diabetes in Brazil,” The Revision of Diabetic Studies, vol. 3, pp. 73–78, 2006. View at Google Scholar
  20. M. B. Gomes, M. Coral, R. A. Cobas et al., “Prevalence of adults with type 1 diabetes who meet the goals of care in daily clinical practice: a nationwide multicenter study in Brazil Diabetes,” Diabetes Research Clinical Practice, vol. 97, no. 1, pp. 63–70, 2012. View at Google Scholar
  21. Sociedade Brasileira de Diabetes: Diretrizes da SBD/2011, AC Farmaceutica Ltda, São Paulo, Brazil, 2011.
  22. R. R. Holman, S. K. Paul, M. A. Bethel, D. R. Matthews, and H. A. W. Neil, “10-Year follow-up of intensive glucose control in type 2 diabetes,” The New England Journal of Medicine, vol. 359, no. 15, pp. 1577–1589, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. W. Duckworth, C. Abraira, T. Moritz et al., “Glucose control and vascular complications in veterans with type 2 diabetes,” The New England Journal of Medicine, vol. 360, no. 2, pp. 129–139, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Patel, S. MacMahon, J. Chalmers et al., “Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes,” The New England Journal of Medicine, vol. 358, no. 24, pp. 2560–2572, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. The Action to Control Cardiovascular Risk in Diabetes Study Group, “Effects of Intensive Glucose Lowering in Type 2 Diabetes,” The New England Journal of Medicine, vol. 358, pp. 2545–2559, 2008. View at Google Scholar
  26. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group, “Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes,” The New England Journal of Medicine, vol. 353, pp. 2643–2653, 2005. View at Google Scholar
  27. A. Ceriello, M. A. Ihnat, and J. E. Thorpe, “The "Metabolic memory": is more than just tight glucose control necessary to prevent diabetic complications?” Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 2, pp. 410–415, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. P. Poirier, T. D. Giles, G. A. Bray et al., “Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss,” Circulation, vol. 113, pp. 898–918, 2006. View at Google Scholar
  29. A. H. Mokdad, B. A. Bowman, E. S. Ford, F. Vinicor, J. S. Marks, and J. P. Koplan, “The continuing epidemics of obesity and diabetes in the United States,” Journal of the American Medical Association, vol. 286, no. 10, pp. 1195–1200, 2001. View at Google Scholar · View at Scopus
  30. B. B. Duncan, M. I. Schmidt, J. S. Pankow et al., “Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study,” Diabetes, vol. 52, no. 7, pp. 1799–1805, 2003. View at Google Scholar · View at Scopus
  31. J. Tuomilehto, J. Lindström, J. G. Eriksson et al., “Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance,” The New England Journal of Medicine, vol. 344, no. 18, pp. 1343–1350, 2001. View at Publisher · View at Google Scholar · View at Scopus
  32. W. C. Knowler, S. E. Fowler, R. F. Hamman et al., “10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study,” The Lancet, vol. 374, pp. 1677–1686, 2009. View at Google Scholar
  33. G. F. Watts and D. A. Playford, “Dyslipoproteinaemia and hyperoxidative stress in the pathogenesis of endothelial dysfunction in non-insulin dependent diabetes mellitus: an hypothesis,” Atherosclerosis, vol. 141, no. 1, pp. 17–30, 1998. View at Google Scholar · View at Scopus
  34. A. S. D. M. Matheus, R. A. Cobas, and M. B. Gomes, “Dyslipidemias in type 1 diabetes: a current approach,” Arquivos Brasileiros de Endocrinologia e Metabologia, vol. 52, no. 2, pp. 334–339, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. C. B. Renard, F. Kramer, F. Johansson et al., “Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions,” Journal of Clinical Investigation, vol. 114, no. 5, pp. 659–668, 2004. View at Publisher · View at Google Scholar · View at Scopus
  36. H. M. Colhoun, D. J. Betteridge, P. N. Durrington et al., “Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial,” The Lancet, vol. 364, no. 9435, pp. 685–696, 2004. View at Publisher · View at Google Scholar · View at Scopus
  37. B. G. Brown, X. Q. Zhao, A. Chait et al., “Sinvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease,” The New England Journal of Medicine, vol. 345, pp. 1583–1592, 2001. View at Google Scholar
  38. J. C. LaRosa, S. M. Grundy, D. D. Waters et al., “Intensive lipid lowering with atorvastatin in patients with stable coronary disease,” The New England Journal of Medicine, vol. 352, no. 14, pp. 1425–1435, 2005. View at Publisher · View at Google Scholar · View at Scopus
  39. N. C. Wanner, V. Krane, W. Marz et al., “Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis,” The New England Journal of Medicine, vol. 353, pp. 238–248, 2005. View at Google Scholar
  40. S. M. Grundy, J. I. Cleeman, C. N. B. Merz et al., “Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines,” Circulation, vol. 110, pp. 227–239, 2004. View at Google Scholar
  41. Cholesterol Treatment Trialists' (CTT) Collaborators, “The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials,” The Lancet, vol. 380, no. 9841, pp. 581–590, 2012. View at Google Scholar
  42. M. V. Furtado and C. A. Polanczyk, “Prevenção cardiovascular em pacientes com diabetes: revisão baseada em evidências,” Arquivos Brasileiros de Endocrinologia e Metabologia, vol. 51, no. 2, pp. 312–318, 2007. View at Google Scholar
  43. The FIELD study investigators, “Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial,” The Lancet, vol. 366, no. 9500, pp. 1849–11861, 2005. View at Google Scholar
  44. A. Keech, P. Mitchell, P. Summanen et al., “Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial,” The Lancet, vol. 370, no. 9600, pp. 1687–1697, 2007. View at Publisher · View at Google Scholar · View at Scopus
  45. Diabetes in America, National Institutes of Health, National Institute of diabetes and Digestive and Kidney Diseases, Bethesda, MD, USA, 2nd edition, 1995.
  46. American Diabetes Association, “Treatment of hypertension in diabetes,” Diabetes Care, vol. 16, pp. 1394–1401, 1993. View at Google Scholar
  47. J. D. Curb, S. L. Pressel, J. A. Cutler et al., “Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension,” Journal of the American Medical Association, vol. 276, no. 23, pp. 1886–1892, 1996. View at Publisher · View at Google Scholar · View at Scopus
  48. C. E. Mogensen, K. W. Hansen, M. M. Pedersen, and C. K. Christensen, “Renal factors influencing blood pressure threshold and choice of treatment for hypertension in IDDM,” Diabetes Care, vol. 14, supplement 4, pp. 13–26, 1991. View at Google Scholar · View at Scopus
  49. R. Turner, I. Stratton, V. Fright, R. Holman, S. Manley, and C. Cull, “Hypertension in Diabetes Study (HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications,” Journal of Hypertension, vol. 11, no. 3, pp. 309–317, 1993. View at Google Scholar · View at Scopus
  50. American Diabetes Association, “Standards of medical care in diabetes-2012,” Diabetes Care, vol. 35, supplement 1, pp. S11–S63, 2012. View at Google Scholar
  51. A. V. Chobanian, G. L. Bakris, H. R. Black et al., “The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report,” Journal of the American Medical Association, vol. 289, no. 19, pp. 2560–2572, 2003. View at Publisher · View at Google Scholar · View at Scopus
  52. G. Maneia, S. Laurent, E. Agabiti-Rosei et al., “Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document,” Journal of Hypertension, vol. 27, no. 11, pp. 2121–2158, 2009. View at Publisher · View at Google Scholar · View at Scopus
  53. A. Patel, “Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial,” The Lancet, vol. 370, no. 9590, pp. 829–840, 2007. View at Publisher · View at Google Scholar · View at Scopus
  54. A. I. Adler, I. M. Stratton, H. A. W. Neil et al., “Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study,” British Medical Journal, vol. 321, no. 7258, pp. 412–419, 2000. View at Google Scholar · View at Scopus
  55. UK Prospective Diabetes Study Group, “Tight blood pressure control and risk of macrovascular and microvascular complications intype 2 diabetes: UKPDS 38,” British Medical Journal, vol. 317, p. 703, 1998. View at Google Scholar
  56. E. J. Roccella, “The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure,” Archives of Internal Medicine, vol. 157, no. 21, pp. 2413–2446, 1997. View at Google Scholar · View at Scopus
  57. The ACCORD Study Group, “Effects of intensive blood-pressure control in type 2 diabetes mellitus,” The New England Journal of Medicine, vol. 362, pp. 1575–1585, 2010. View at Google Scholar
  58. C. Berry, M. J. Brosnan, J. Fennell, C. A. Hamilton, and A. F. Dominiczak, “Oxidative stress and vascular damage in hypertension,” Current Opinion in Nephrology and Hypertension, vol. 10, no. 2, pp. 247–255, 2001. View at Publisher · View at Google Scholar · View at Scopus
  59. K. K. Griendling, “Novel NAD(P)H oxidases in the cardiovascular system,” Heart, vol. 90, no. 5, pp. 491–493, 2004. View at Google Scholar · View at Scopus
  60. M. S. Goligorsky, “Making sense out of oxygen sensor,” Circulation Research, vol. 86, no. 8, pp. 824–826, 2000. View at Google Scholar · View at Scopus
  61. U. Bayraktutan, L. Blayney, and A. M. Shah, “Molecular characterization and localization of the NAD(P)H oxidase components gp91-phox and p22-phox in endothelial cells,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 20, no. 8, pp. 1903–1911, 2000. View at Google Scholar · View at Scopus
  62. T. Fukui, B. Lassegue, H. Kai et al., “Cytochrome b558 alpha subunit cloning and expression in rat aortic smooth muscle cells,” Biochimica et Biophysica Acta, vol. 231, pp. 215–219, 1995. View at Google Scholar
  63. T. Chabrashvili, A. Tojo, M. L. Onozato et al., “Expression and cellular localization of classic NADPH oxidase subunits in the spontaneously hypertensive rat kidney,” Hypertension, vol. 39, no. 2 I, pp. 269–274, 2002. View at Publisher · View at Google Scholar · View at Scopus
  64. H. Azumi, N. Inoue, S. Takeshita et al., “Expression of NADH/NADPH oxidase p22(phox) in human coronary arteries,” Circulation, vol. 100, no. 14, pp. 1494–1498, 1999. View at Google Scholar · View at Scopus
  65. S. Greiber, T. Munzel, S. Kastner et al., “NAD(P)H oxidase activity in cultured human podocytes: effects of adenosine triphosphate,” Kidney International, vol. 53, pp. 654–663, 1998. View at Google Scholar
  66. S. A. Jones, J. T. Hancock, O. T. G. Jones, A. Neubauer, and N. Topley, “The expression of NADPH oxidase components in human glomerular mesangial cells: detection of protein and mRNA for p47phox, p67phox, and p22phox,” Journal of the American Society of Nephrology, vol. 5, no. 7, pp. 1483–1491, 1995. View at Google Scholar · View at Scopus
  67. N. Inoue, S. Kawashima, K. Kanazawa, S. Yamada, H. Akita, and M. Yokoyama, “Polymorphism of the NADH/NADPH oxidase p22 phox gene in patients with coronary artery disease,” Circulation, vol. 97, no. 2, pp. 135–137, 1998. View at Google Scholar · View at Scopus
  68. L. Van Heerebeek, C. Meischl, W. Stooker, C. J. L. M. Meijer, H. W. M. Niessen, and D. Roos, “NADPH oxidase: new source of reactive oxygen species in the vascular system?” Journal of Clinical Pathology, vol. 55, no. 8, pp. 561–568, 2002. View at Publisher · View at Google Scholar · View at Scopus
  69. M. A. Ihnat, J. E. Thorpe, C. D. Kamat et al., “Reactive oxygen species mediate a cellular “memory” of high glucose stress signaling,” Diabetologia, vol. 50, pp. 1523–1531, 2007. View at Google Scholar
  70. K. M. Channon and T. J. Guzik, “Mechanisms of superoxide production in human blood vessels: relationship to endothelial dysfunction, clinical and genetic risk factors,” Journal of Physiology and Pharmacology, vol. 53, no. 4 I, pp. 515–524, 2002. View at Google Scholar · View at Scopus
  71. S. W. Ballinger, C. Patterson, C. N. Yan et al., “Hydrogen peroxide- and peroxynitrite-induced mitochondrial DNA damage and dysfunction in vascular endothelial and smooth muscle cells,” Circulation Research, vol. 86, no. 9, pp. 960–966, 2000. View at Google Scholar · View at Scopus
  72. A. Ceriello, A. Morocutti, F. Mercuri et al., “Defective intracellular antioxidant enzyme production in type 1 diabetic patients with nephropathy,” Diabetes, vol. 49, no. 12, pp. 2170–2177, 2000. View at Google Scholar · View at Scopus
  73. G. Marra, P. Cotroneo, D. Pitocco et al., “Early increase of oxidative stress and reduced antioxidant defenses in patients with uncomplicated type 1 diabetes: a case for gender difference,” Diabetes Care, vol. 25, no. 2, pp. 370–375, 2002. View at Publisher · View at Google Scholar · View at Scopus
  74. A. Strasak, E. Ruttmann, L. Brant et al., “Serum uric acid and risk of cardiovascular mortality: a prospective long-term study of 83 683 Austrian men,” Clinical Chemistry, vol. 54, no. 2, pp. 273–284, 2008. View at Publisher · View at Google Scholar · View at Scopus
  75. W. S. Waring, J. A. McKnight, D. J. Webb, and S. R. J. Maxwell, “Uric acid restores endothelial function in patients with type 1 diabetes and regular smokers,” Diabetes, vol. 55, no. 11, pp. 3127–3132, 2006. View at Publisher · View at Google Scholar · View at Scopus
  76. A. S. M. Matheus, E. Tibiriçá, P. B. da Silva et al., “Uric acid levels are associated with microvascular endothelial dysfunction in patients with type 1 diabetes,” Diabetic Medicine, vol. 28, no. 10, pp. 1188–1193, 2011. View at Google Scholar
  77. T. Costacou, R. E. Ferrell, and T. J. Orchard, “Haptoglobin genotype a determinant of cardiovascular complication risk in type 1 diabetes,” Diabetes, vol. 57, no. 6, pp. 1702–1706, 2008. View at Publisher · View at Google Scholar · View at Scopus
  78. M. Vardi, S. Blum, and A. P. Levy, “Haptoglobin genotype and cardiovascular outcomes in diabetes mellitus-natural history of the disease and the effect of vitamin E treatment. Meta-analysis of the medical literature,” European Journal of Internal Medicine, vol. 23, no. 7, pp. 628–632, 2001. View at Google Scholar
  79. A. P. Levy, I. Hochberg, K. Jablonski et al., “Haptoglobin phenotype is an independent risk factor for cardiovascular disease in individuals with diabetes: the strong heart study,” Journal of the American College of Cardiology, vol. 40, no. 11, pp. 1984–1990, 2002. View at Publisher · View at Google Scholar · View at Scopus
  80. C. Ling and L. Groop, “Epigenetics: a molecular link between environmental factors and type 2 diabetes,” Diabetes, vol. 58, no. 12, pp. 2718–2725, 2009. View at Publisher · View at Google Scholar · View at Scopus
  81. A. El-Osta, D. Brasacchio, D. Yao et al., “Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia,” The Journal of Experimental Medicine, vol. 205, no. 10, pp. 2409–2417, 2008. View at Google Scholar
  82. R. M. Millis, “Epigentics and hypertension,” Current Hypertension Reports, vol. 13, pp. 21–28, 2011. View at Google Scholar
  83. R. Stoger, “Epigenetics and obesity,” Pharmacogenomics, vol. 9, pp. 1851–1860, 2008. View at Google Scholar
  84. G. S. Hotamisligil, “Inflammation and metabolic disorders,” Nature, vol. 444, no. 7121, pp. 860–867, 2006. View at Publisher · View at Google Scholar · View at Scopus
  85. S. E. Shoelson, J. Lee, and A. B. Goldfine, “Inflammation and insulin resistance,” Journal of Clinical Investigation, vol. 116, no. 7, pp. 1793–1801, 2006. View at Publisher · View at Google Scholar · View at Scopus
  86. B. Vicenova, V. Vopalensky, L. Burysek et al., “Emerging role of interleukin-1 in cardiovascular disease,” Physiology Research, vol. 58, pp. 481–498, 2009. View at Google Scholar
  87. D. A. F. Ferrarezi, N. Cheurfa, A. F. Reis, F. Fumeron, and G. Velho, “Adiponectin gene and cardiovascular risk in type 2 diabetic patients: a review of evidences,” Arquivos Brasileiros de Endocrinologia e Metabologia, vol. 51, no. 2, pp. 153–159, 2007. View at Google Scholar · View at Scopus
  88. H. Ait-Oufella, S. Taleb, Z. Mallat et al., “Recent advances on the role of cytokines in atherosclerosis,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 31, pp. 969–979, 2011. View at Google Scholar
  89. K. E. Wellen and G. S. Hotamisligil, “Inflammation, stress, and diabetes,” Journal of Clinical Investigation, vol. 115, no. 5, pp. 1111–1119, 2005. View at Publisher · View at Google Scholar · View at Scopus
  90. R. A. DeFronzo, “Pathogenesis of type 2 diabetes mellitus,” Medical Clinics of North America, vol. 88, no. 4, pp. 787–835, 2004. View at Publisher · View at Google Scholar · View at Scopus
  91. I. G. Poornima, P. Parikh, and R. P. Shannon, “Diabetic cardiomyopathy: the search for a unifying hypothesis,” Circulation Research, vol. 98, no. 5, pp. 596–605, 2006. View at Publisher · View at Google Scholar · View at Scopus
  92. A. D. Pradhan, J. E. Manson, N. Rifai, J. E. Buring, and P. M. Ridker, “C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus,” Journal of the American Medical Association, vol. 286, no. 3, pp. 327–334, 2001. View at Google Scholar · View at Scopus
  93. A. Chait, Y. H. Chang, J. F. Oram, and J. W. Heinecke, “Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease?” Journal of Lipid Research, vol. 46, no. 3, pp. 389–403, 2005. View at Publisher · View at Google Scholar · View at Scopus
  94. T. Yamauchi, J. Kamon, Y. Minokoshi et al., “Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase,” Nature Medicine, vol. 8, pp. 1288–1295, 2002. View at Google Scholar
  95. R. Yang and L. A. Barouch, “Leptin signaling and obesity: cardiovascular consequences,” Circulation Research, vol. 101, no. 6, pp. 545–559, 2007. View at Publisher · View at Google Scholar · View at Scopus
  96. B. Basha, S. M. Samuel, C. R. Triggle et al., “Endothelial dysfunction in diabetes mellitus: possible involvement of endoplasmic reticulum stress?” Experimental Diabetes Research, vol. 2012, Article ID 481840, 14 pages, 2012. View at Publisher · View at Google Scholar
  97. M. Romano, M. Pomilio, S. Vigneri et al., “Endothelial perturbation in children and adolescents with type 1 diabetes: association with markers of the inflammatory reaction,” Diabetes Care, vol. 24, no. 9, pp. 1674–1678, 2001. View at Google Scholar · View at Scopus
  98. H. A. R. Hadi and J. A. Al Suwaidi, “Endothelial dysfunction in diabetes mellitus,” Vascular Health and Risk Management, vol. 3, no. 6, pp. 853–876, 2007. View at Google Scholar · View at Scopus
  99. J. Yan, G. Tie, B. Park, Y. Yan, P. T. Nowicki, and L. M. Messina, “Recovery from hind limb ischemia is less effective in type 2 than in type 1 diabetic mice: roles of endothelial nitric oxide synthase and endothelial progenitor cells,” Journal of Vascular Surgery, vol. 50, no. 6, pp. 1412–1422, 2009. View at Publisher · View at Google Scholar · View at Scopus
  100. L. Hazel, A. Kenneth, and O. Roebuck, “Oxidant stress and endothelial cell dysfunction,” American Journal of Physiology, vol. 280, pp. C719–C741, 2001. View at Google Scholar
  101. D. Versari, E. Daghini, A. Virdis, L. Ghiadoni, and S. Taddei, “Endothelial dysfunction as a target for prevention of cardiovascular disease.,” Diabetes care, vol. 32, pp. S314–321, 2009. View at Google Scholar · View at Scopus
  102. R. A. P. Skyrme-Jones, R. C. O'Brien, M. Luo, and I. T. Meredith, “Endothelial vasodilator function is related to low-density lipoprotein particle size and low-density lipoprotein vitamin E content in type 1 diabetes,” Journal of the American College of Cardiology, vol. 35, no. 2, pp. 292–299, 2000. View at Publisher · View at Google Scholar · View at Scopus
  103. M. B. Gomes, A. S. M. Matheus, and E. Tibiriçá, “Evaluation of microvascular endothelial function in patients with type 1 diabetes using laser-Doppler perfusion monitoring: which method to choose?” Microvascular Research, vol. 76, no. 2, pp. 132–133, 2008. View at Publisher · View at Google Scholar · View at Scopus
  104. E. Tibiriçá, E. Rodrigues, R. A. Cobas et al., “Endothelial function in patients with type 1 diabetes evaluated by skin capillary recruitment,” Microvascular Research, vol. 73, pp. 107–112, 2007. View at Google Scholar
  105. A. Koitka, P. Abraham, B. Bouhanick et al., “Impaired pressure-induced vasodilation at the foot in young adults with type 1 diabetes,” Diabetes, vol. 53, pp. 721–725, 2005. View at Google Scholar
  106. N. N. Chan, P. Vallance, and H. M. Colhoun, “Endothelium-dependent and -independent vascular dysfunction in type 1 diabetes: role of conventional risk factors, sex, and glycemic control,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 6, pp. 1048–1054, 2003. View at Publisher · View at Google Scholar · View at Scopus
  107. M. T. Schram, N. Chaturvedi, C. Schalkwijk et al., “Vascular risk factors and markers of endothelial function as determinants of inflammatory markers in type 1 diabetes: the EURODIAB prospective complications study,” Diabetes Care, vol. 26, no. 7, pp. 2165–2173, 2003. View at Publisher · View at Google Scholar · View at Scopus
  108. F. Khan, T. A. Elhadd, S. A. Greene, and J. J. F. Belch, “Impaired skin microvascular function in children, adolescents, and young adults with type I diabetes,” Diabetes Care, vol. 23, no. 2, pp. 215–220, 2000. View at Google Scholar · View at Scopus
  109. M. B. Gomes, R. A. Cobas, E. Nunes et al., “Plasma PAF-acetylhydrolase activity, inflammatory markers and susceptibility of LDL to in vitro oxidation in patients with type 1 diabetes mellitus,” Diabetes Research and Clinical Practice, vol. 85, pp. 61–68, 2009. View at Google Scholar
  110. S. Devaraj, N. Glaser, S. Griffen, J. Wang-Polagruto, E. Miguelino, and I. Jialal, “Increased monocytic activity and biomarkers of inflammation in patients with type 1 diabetes,” Diabetes, vol. 55, no. 3, pp. 774–779, 2006. View at Google Scholar · View at Scopus
  111. G. K. Kolluru, S. C. Bir, and C. G. Kevil, “Endothelial dysfunction and diabetes: effects on angiogenesis, vascular remodeling and wound healing,” International Journal of Vascular Medicine, vol. 2012, Article ID 918267, 30 pages, 2012. View at Publisher · View at Google Scholar
  112. T. J. Stalker, C. B. Skvarka, and R. Scalia, “A novel role for calpains in the endothelial dysfunction of hyperglycemia.,” The FASEB Journal, vol. 17, no. 11, pp. 1511–1513, 2003. View at Google Scholar · View at Scopus
  113. B. M. Balletshofer, K. Rittig, M. D. Enderle et al., “Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance,” Circulation, vol. 101, no. 15, pp. 1780–1784, 2000. View at Google Scholar · View at Scopus
  114. L. C. Rolim, J. R. Sá, A. R. Chacra, and S. A. Dib, “Diabetic cardiovascular autonomic neuropathy: risk factors, clinical impact and early diagnosis.,” Arquivos brasileiros de cardiologia, vol. 90, no. 4, pp. e24–31, 2008. View at Google Scholar · View at Scopus
  115. A. I. Vinik and D. Ziegler, “Diabetic cardiovascular autonomic neuropathy,” Circulation, vol. 115, no. 3, pp. 387–397, 2007. View at Publisher · View at Google Scholar · View at Scopus
  116. A. I. Vinik, R. E. Maser, and D. Ziegler, “Autonomic imbalance: prophet of doom or scope for hope?” Diabetic Medicine, vol. 28, no. 6, pp. 643–651, 2011. View at Publisher · View at Google Scholar · View at Scopus
  117. R. Lampert, J. D. Bremner, S. Su et al., “Decreased heart rate variability is associated with higher levels of inflammation in middle-aged men,” American Heart Journal, vol. 156, no. 4, pp. 759–767, 2008. View at Publisher · View at Google Scholar · View at Scopus
  118. C. T. Prince, A. M. Secrest, R. H. Mackey, V. C. Arena, L. A. Kingsley, and T. J. Orchard, “Cardiovascular autonomic neuropathy, HDL cholesterol, and smoking correlate with arterial stiffness markers determined 18 years later in type 1 diabetes,” Diabetes Care, vol. 33, no. 3, pp. 652–657, 2010. View at Publisher · View at Google Scholar · View at Scopus
  119. H. Schmid, “Impacto cardiovascular da neuropatia autonômica do diabetes mellitus,” Arquivos Brasileiros de Endocrinologia e Metabologia, vol. 51, pp. 232–243, 2007. View at Google Scholar
  120. L. H. Young, F. J. T. Wackers, D. A. Chyun et al., “Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes the DIAD study: a randomized controlled trial,” Journal of the American Medical Association, vol. 301, no. 15, pp. 1547–1555, 2009. View at Publisher · View at Google Scholar · View at Scopus
  121. J. T. H. Frans, F. J. T. Wackers, L. H. Young et al., “Detection of silent myocardial ischemia in asymptomatic diabetic subjects,” Diabetes Care, vol. 27, pp. 1954–1961, 2004. View at Google Scholar
  122. W. E. Boden, R. A. O’Rourke, K. K. Teo et al., “Optimal medical therapy with or without PCI for stable coronary disease,” The New England Journal of Medicine, vol. 356, pp. 1503–1516, 2007. View at Google Scholar
  123. R. L. Frye, P. August, M. M. Brooks et al., “A randomized trial of therapies for type 2 diabetes and coronary artery disease,” The New England Journal of Medicine, vol. 360, pp. 2503–2515, 2009. View at Google Scholar
  124. J. J. Bax, L. H. Young, R. L. Frye, R. O. Bonow, H. O. Steinberg, and E. J. Barrett, “Screening for coronary artery disease in patients with diabetes,” Diabetes Care, vol. 30, no. 10, pp. 2729–2736, 2007. View at Publisher · View at Google Scholar · View at Scopus
  125. C. S. Fox, L. Sullivan, R. B. D'Agostino, and P. W. F. Wilson, “The significant effect of diabetes duration on coronary heart disease mortality: the framingham heart study,” Diabetes Care, vol. 27, no. 3, pp. 704–708, 2004. View at Publisher · View at Google Scholar · View at Scopus
  126. P. Raggi, T. Q. Callister, B. Cooil et al., “Identification of patients at increased risk of first unheralded acute myocardial infarction by electron-beam computed tomography,” Circulation, vol. 101, no. 8, pp. 850–855, 2000. View at Google Scholar · View at Scopus
  127. P. Raggi, B. Cooil, and T. Q. Callister, “Use of electron beam tomography data to develop models for prediction of hard coronary events,” American Heart Journal, vol. 141, no. 3, pp. 375–382, 2001. View at Publisher · View at Google Scholar · View at Scopus
  128. D. Jasinowodolinski and G. Szarf, “Calcium score in the cardiovascular evaluation of the diabetic patient,” Arquivos Brasileiros de Endocrinologia e Metabologia, vol. 51, no. 2, pp. 294–298, 2007. View at Google Scholar · View at Scopus
  129. J. A. Hoff, E. V. Chomka, A. J. Krainik, M. Daviglus, S. Rich, and G. T. Kondos, “Age and gender distributions of coronary artery calcium detected by electron beam tomography in 35,246 adults,” American Journal of Cardiology, vol. 87, no. 12, pp. 1335–1339, 2001. View at Publisher · View at Google Scholar · View at Scopus
  130. W. R. Janowitz, A. S. Agatston, G. Kaplan, and M. Viamonte, “Differences in prevalence and extent of coronary artery calcium detected by ultrafast computed tomography in asymptomatic men and women,” American Journal of Cardiology, vol. 72, no. 3, pp. 247–254, 1993. View at Publisher · View at Google Scholar · View at Scopus
  131. S. Malik, M. J. Budoff, R. Katz et al., “Impact of subclinical atherosclerosis on cardiovascular disease events in individuals with metabolic syndrome and diabetes. The multi-etnic study of atherosclerosis,” Diabetes Care, vol. 4, pp. 2285–2290, 2011. View at Google Scholar
  132. P. Greenland, J. S. Alpert, G. A. Beller et al., “2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults,” Journal of the American College of Cardiology, vol. 56, no. 25, pp. e50–e103, 2010. View at Publisher · View at Google Scholar · View at Scopus
  133. Y. Irie, N. Katakami, H. Kaneto et al., “Maximum carotid intima-media thickness improves the prediction ability of coronary artery stenosis in type 2 diabetic patients without history of coronary artery disease,” Atherosclerosis, vol. 221, no. 2, pp. 438–444, 2012. View at Google Scholar
  134. J. F. Polak, J. Y. C. Backlund, P. A. Cleary et al., “Progression of carotid artery intima-media thickness during 12 years in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study,” Diabetes, vol. 60, no. 2, pp. 607–613, 2011. View at Publisher · View at Google Scholar · View at Scopus
  135. E. R. Mohler, “Peripheral arterial disease: identification and implications,” Archives of Internal Medicine, vol. 163, no. 19, pp. 2306–2314, 2003. View at Publisher · View at Google Scholar · View at Scopus
  136. A. T. Hirsch, Z. J. Haskal, N. R. Hertzer et al., “ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional,” Journal of the American College of Cardiology., vol. 47, no. 6, pp. 1239–1312, 2006. View at Google Scholar · View at Scopus
  137. B. Doza, M. Kaur, S. Chopra et al., “Cardiovascular risk factors and distributions of the ankle brachial index among type 2 diabetes mellitus patients,” International Journal of Hypertension, vol. 2012, Article ID 485812, 6 pages, 2012. View at Publisher · View at Google Scholar